• Something wrong with this record ?

Prognostic relevance of the C-X-C motif chemokine ligand 13 and interleukin-8 in predicting the transition from clinically isolated syndrome to multiple sclerosis

K. Klíčová, J. Mareš, O. Sobek, Z. Rous, M. Rous, M. Raška, HP. Hartung

. 2024 ; 59 (11) : 2955-2966. [pub] 20240307

Language English Country France

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc24013762

Grant support
NV19-05-00191 Ministry of Health of the Czech Republic
IGA_LF_2022_035 Palacky University

The initial phase of multiple sclerosis (MS), often known as clinically isolated syndrome (CIS), is a critical period for identifying individuals at high risk of progressing to full-blown MS and initiating timely treatment. In this study, we aimed to evaluate the prognostic value of C-X-C motif chemokine ligand 13 (CXCL13) and interleukin-8 (IL-8) as potential markers for CIS patients' conversion to MS. Our study encompassed patients with CIS, those with relapsing-remitting MS (RRMS), and control subjects, with sample analysis conducted on both cerebrospinal fluid (CSF) and serum. Patients were categorized into four groups: CIS-CIS (no MS development within 2 years), CIS-RRMS (conversion to RRMS within 2 years), RRMS (already diagnosed), and a control group (CG) with noninflammatory central nervous system disorders. Results showed significantly elevated levels of CXCL13 in CSF across all patient groups compared with the CG (p < 0.0001, Kruskal-Wallis test). Although CXCL13 concentrations were slightly higher in the CIS-RRMS group, statistical significance was not reached. Similarly, significantly higher levels of IL-8 were detected in CSF samples from all patient groups compared with the CG (p < 0.0001, Kruskal-Wallis test). Receiver operating characteristic analysis in the CIS-RRMS group identified both CXCL13 (area under receiver operating characteristic curve = .959) and IL-8 (area under receiver operating characteristic curve = .939) in CSF as significant predictors of CIS to RRMS conversion. In conclusion, our study suggests a trend towards elevated CSF IL-8 and CSF CXCL13 levels in CIS patients progressing to RRMS. These findings emphasize the importance of identifying prognostic markers to guide appropriate treatment strategies for individuals in the early stages of MS.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24013762
003      
CZ-PrNML
005      
20240905134039.0
007      
ta
008      
240725s2024 fr f 000 0|eng||
009      
AR
024    7_
$a 10.1111/ejn.16300 $2 doi
035    __
$a (PubMed)38453679
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a fr
100    1_
$a Klíčová, Kateřina $u Department of Neurology, Faculty of Medicine and Dentistry, Palacký University and University Hospital, Olomouc, Czech Republic $1 https://orcid.org/0000000275284146
245    10
$a Prognostic relevance of the C-X-C motif chemokine ligand 13 and interleukin-8 in predicting the transition from clinically isolated syndrome to multiple sclerosis / $c K. Klíčová, J. Mareš, O. Sobek, Z. Rous, M. Rous, M. Raška, HP. Hartung
520    9_
$a The initial phase of multiple sclerosis (MS), often known as clinically isolated syndrome (CIS), is a critical period for identifying individuals at high risk of progressing to full-blown MS and initiating timely treatment. In this study, we aimed to evaluate the prognostic value of C-X-C motif chemokine ligand 13 (CXCL13) and interleukin-8 (IL-8) as potential markers for CIS patients' conversion to MS. Our study encompassed patients with CIS, those with relapsing-remitting MS (RRMS), and control subjects, with sample analysis conducted on both cerebrospinal fluid (CSF) and serum. Patients were categorized into four groups: CIS-CIS (no MS development within 2 years), CIS-RRMS (conversion to RRMS within 2 years), RRMS (already diagnosed), and a control group (CG) with noninflammatory central nervous system disorders. Results showed significantly elevated levels of CXCL13 in CSF across all patient groups compared with the CG (p < 0.0001, Kruskal-Wallis test). Although CXCL13 concentrations were slightly higher in the CIS-RRMS group, statistical significance was not reached. Similarly, significantly higher levels of IL-8 were detected in CSF samples from all patient groups compared with the CG (p < 0.0001, Kruskal-Wallis test). Receiver operating characteristic analysis in the CIS-RRMS group identified both CXCL13 (area under receiver operating characteristic curve = .959) and IL-8 (area under receiver operating characteristic curve = .939) in CSF as significant predictors of CIS to RRMS conversion. In conclusion, our study suggests a trend towards elevated CSF IL-8 and CSF CXCL13 levels in CIS patients progressing to RRMS. These findings emphasize the importance of identifying prognostic markers to guide appropriate treatment strategies for individuals in the early stages of MS.
650    _2
$a lidé $7 D006801
650    12
$a chemokin CXCL13 $x mozkomíšní mok $x krev $7 D054382
650    12
$a interleukin-8 $x mozkomíšní mok $x krev $7 D016209
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a dospělí $7 D000328
650    _2
$a prognóza $7 D011379
650    12
$a progrese nemoci $7 D018450
650    12
$a relabující-remitující roztroušená skleróza $x mozkomíšní mok $x krev $x diagnóza $7 D020529
650    _2
$a biologické markery $x mozkomíšní mok $x krev $7 D015415
650    _2
$a lidé středního věku $7 D008875
650    _2
$a demyelinizační nemoci $x mozkomíšní mok $7 D003711
650    _2
$a roztroušená skleróza $x mozkomíšní mok $x krev $x diagnóza $7 D009103
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
700    1_
$a Mareš, Jan $u Department of Neurology, Faculty of Medicine and Dentistry, Palacký University and University Hospital, Olomouc, Czech Republic
700    1_
$a Sobek, Ondřej $u Laboratory for Cerebrospinal Fluid, Neuroimmunology, Pathology and Special Diagnostics, Topelex, Prague, Czech Republic
700    1_
$a Rous, Zuzana $u Department of Neurology, Faculty of Medicine and Dentistry, Palacký University and University Hospital, Olomouc, Czech Republic
700    1_
$a Rous, Matouš $u Department of Neurology, Faculty of Medicine and Dentistry, Palacký University and University Hospital, Olomouc, Czech Republic
700    1_
$a Raška, Milan $u Department of Immunology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
700    1_
$a Hartung, Hans-Peter $u Department of Neurology, Faculty of Medicine and Dentistry, Palacký University and University Hospital, Olomouc, Czech Republic $u Department of Neurology, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany $u Brain and Mind Center, University of Sydney, Sydney, New South Wales, Australia
773    0_
$w MED00011483 $t European journal of neuroscience $x 1460-9568 $g Roč. 59, č. 11 (2024), s. 2955-2966
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38453679 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240725 $b ABA008
991    __
$a 20240905134033 $b ABA008
999    __
$a ok $b bmc $g 2143521 $s 1225628
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 59 $c 11 $d 2955-2966 $e 20240307 $i 1460-9568 $m European journal of neuroscience $n Eur J Neurosci $x MED00011483
GRA    __
$a NV19-05-00191 $p Ministry of Health of the Czech Republic
GRA    __
$a IGA_LF_2022_035 $p Palacky University
LZP    __
$a Pubmed-20240725

Find record

Citation metrics

Archiving options